Lebrikizumab
- Generic Name
- Lebrikizumab
- Brand Names
- Ebglyss
- Drug Type
- Biotech
- CAS Number
- 953400-68-5
- Unique Ingredient Identifier
- U9JLP7V031
- Background
Lebrikizumab has been used in trials studying the treatment of Asthma, Allergic Asthma, Atopic Dermatitis, Idiopathic Pulmonary Fibrosis, and COPD, Chronic Obstructive Pulmonary Disease.
A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis
- Conditions
- Atopic Hand and Foot Dermatitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-04-10
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 206
- Registration Number
- NCT06921759
- Locations
- 🇯🇵
Pansy Skin Clinic, Saitama, Japan
🇰🇷The Catholic University of Korea, Incheon St. Mary's Hospital, Bupyeong-gu, Incheon-gwangyeoksi [Incheon], Korea, Republic of
🇰🇷Korea University Ansan Hospital, Ansan-si, Kyǒnggi-do, Korea, Republic of
Lebrikizumab in Moderate-to-severe Atopic Dermatitis
- First Posted Date
- 2025-04-02
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Johann E Gudjonsson MD PhD
- Target Recruit Count
- 48
- Registration Number
- NCT06906497
- Locations
- 🇺🇸
Physioseq USA - CA, Folsom, California, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
🇩🇪University of Freiburg, Freiburg im Breisgau, Germany
A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
- Conditions
- Dermatitis, AtopicEczema
- Interventions
- Other: Placebo
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 520
- Registration Number
- NCT06526182
- Locations
- 🇪🇸
Hospital del Mar - Parc de Salut Mar, Barcelona, Spain
🇪🇸Hospital General Universitario Dr. Balmis, Alicante, Spain
🇪🇸Hospital Universitario Clínico San Cecilio, Granada, Spain
Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 55
- Registration Number
- NCT06444165
- Locations
- 🇺🇸
Concentrics Research, Indianapolis, Indiana, United States
A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- Interventions
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 510
- Registration Number
- NCT06338995
- Locations
- 🇯🇵
8-2 Otemachi, Shizuoka, Japan
🇺🇸AllerVie Clinical Research, Birmingham, Alabama, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
- Conditions
- Perennial Allergic Rhinitis (PAR)
- Interventions
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 450
- Registration Number
- NCT06339008
- Locations
- 🇰🇷
Clinical trial Pharmacy, Seoul, Korea, Republic of
🇵🇱Polimedica PTG Kielce, Kielce, Poland
🇵🇱Centrum Medyczne Promed ul. Olszańska 5G, Krakow, Poland
A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 430
- Registration Number
- NCT06280716
- Locations
- 🇨🇳
Wannan Medical College Yijishan Hospital, Wuhu, Anhui, China
🇨🇳China-Japan Friendship Hospital, Beijing, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
A Study to Investigate the Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese Participants
- First Posted Date
- 2024-02-06
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT06243198
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 240
- Registration Number
- NCT05990725
- Locations
- 🇳🇱
Site 41, Utrecht, Netherlands
🇬🇧Site 38, Leeds, United Kingdom
🇬🇧Site 14, York, United Kingdom
Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 200
- Registration Number
- NCT05916365
- Locations
- 🇩🇪
Investigator Site 11, Münster, Nordrhein-Westfalen, Germany
🇩🇪Investigator Site 7, Darmstadt, Hessen, Germany
🇩🇪Investigator Site 9, Osnabrück, Lower Saxony, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.